Moreover, the IFN signature (including IFI44L and other genes) can predict the sensitivity of RA patients to rituximab (RTX) with excellent ROC analysis (an AUC of 0.87) (102). This evidence concerns the gene IFNA1 and rheumatoid arthritis.